Medicaid “Best Price” Should Guide Medicare ASP Calculations, CMS Says
Executive Summary
The Centers for Medicare & Medicaid Services is advising pharmaceutical manufacturers to look at Medicaid "best price" reporting requirements for guidance when calculating "average sales price" for Medicare Part B drugs
You may also be interested in...
Medicare Law Causes Roche To Hesitate On Oncology Price Increases
Roche and Genentech are holding off on price increases in their oncology portfolio to avoid causing more confusion about reimbursement rates, Roche said
Average Sales Price Formula Could Lead To Negative ASP – PhRMA
The Pharmaceutical Research & Manufacturers of America is urging CMS to change the proposed methodology for including rebates in the calculation of "average sales price.
Medicare Law Causes Roche To Hesitate On Oncology Price Increases
Roche and Genentech are holding off on price increases in their oncology portfolio to avoid causing more confusion about reimbursement rates, Roche said